TY - JOUR
T1 - A research and development (R&D) roadmap for broadly protective coronavirus vaccines
T2 - A pandemic preparedness strategy
AU - The Coronavirus Vaccines R&D Roadmap Taskforce
AU - Moore, Kristine A.
AU - Leighton, Tabitha
AU - Ostrowsky, Julia T.
AU - Anderson, Cory J.
AU - Danila, Richard N.
AU - Ulrich, Angela K.
AU - Lackritz, Eve M.
AU - Mehr, Angela J.
AU - Baric, Ralph S.
AU - Baylor, Norman W.
AU - Gellin, Bruce G.
AU - Gordon, Jennifer L.
AU - Krammer, Florian
AU - Perlman, Stanley
AU - Rees, Helen V.
AU - Saville, Melanie
AU - Weller, Charlotte L.
AU - Osterholm, Michael T.
N1 - Funding Information:
Funding: The work for this project was completed with funding from the Bill & Melinda Gates Foundation (Award #: INV-040729) and The Rockefeller Foundation (Award #: 2022 HTH 002). The findings and conclusions contained within this report are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation or The Rockefeller Foundation.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/3/24
Y1 - 2023/3/24
N2 - Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.
AB - Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused by novel coronaviruses. The Coronavirus Vaccines Research and Development (R&D) Roadmap (CVR) is aimed at promoting the development of such vaccines. The CVR, funded by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, was generated through a collaborative and iterative process, which was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota and involved 50 international subject matter experts and recognized leaders in the field. This report summarizes the major issues and areas of research outlined in the CVR and identifies high-priority milestones. The CVR covers a 6-year timeframe and is organized into five topic areas: virology, immunology, vaccinology, animal and human infection models, and policy and finance. Included in each topic area are key barriers, gaps, strategic goals, milestones, and additional R&D priorities. The roadmap includes 20 goals and 86 R&D milestones, 26 of which are ranked as high priority. By identifying key issues, and milestones for addressing them, the CVR provides a framework to guide funding and research campaigns that promote the development of broadly protective coronavirus vaccines.
KW - Broadly protective coronavirus vaccines
KW - COVID-19 vaccines
KW - Coronavirus
KW - Coronavirus vaccines
KW - Pandemic preparedness
KW - Roadmap
KW - Vaccine research
UR - http://www.scopus.com/inward/record.url?scp=85149685903&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.02.032
DO - 10.1016/j.vaccine.2023.02.032
M3 - Review article
C2 - 36870874
AN - SCOPUS:85149685903
SN - 0264-410X
VL - 41
SP - 2101
EP - 2112
JO - Vaccine
JF - Vaccine
IS - 13
ER -